Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22023802 | 0.93 | CNR2 (0.36) | CNR1CNR2 | |
| SCHEMBL23845817 | 0.89 | — | — | |
| SCHEMBL22024734 | 0.82 | KMT2A (0.30) | — | |
| SCHEMBL23709527 | 0.81 | KDR (0.31) | — | |
| SCHEMBL22023930 | 0.79 | KDR (0.32) | CNR2 | |
| SCHEMBL19788362 | 0.79 | KDR (0.32) | CNR2 | |
| SCHEMBL21719823 | 0.79 | KDR (0.32) | CNR2 | |
| SCHEMBL7179426 | 0.75 | TAAR1 (0.34) | — | |
| SCHEMBL12993678 | 0.75 | SHBG (0.32) | — | |
| SCHEMBL20712774 | 0.73 | PDE4A (0.35) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167150-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | GLYCOMIMETICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167150-A1 | CD33 LIGANDS SUITABLE FOR INCORPORATION INTO CARRIERS | SIGLEC7, SIGLEC9, CD47 | CNR1 3682/4885CNR2 4065/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | CNR1 2040/4885CNR2 2902/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | CNR1 2040/4885CNR2 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.